World-Pharmacists-Day-Insert
X

Find Novel Immunology Drugs in Clinical Development in KOREA, REPUBLIC OF

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mesenchymal stem cells

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Avacta Group

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 08, 2020

            Details:

            The joint venture will develop a new class of MSCs that are primed to produce Affimer proteins to enhance the immune-modulatory effect when administered to patients.